CLINICAL TRIALS PROFILE FOR PROPECIA
✉ Email this page to a colleague
All Clinical Trials for PROPECIA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00381108 ↗ | Study of the Effects of Pomegranate Tablets on Enlarged Prostates | Unknown status | Jarrow Pharmaceuticals | Phase 1 | 2005-09-01 | To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia. |
| NCT00381108 ↗ | Study of the Effects of Pomegranate Tablets on Enlarged Prostates | Unknown status | Pomegranate Health | Phase 1 | 2005-09-01 | To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia. |
| NCT00381108 ↗ | Study of the Effects of Pomegranate Tablets on Enlarged Prostates | Unknown status | University of California, Irvine | Phase 1 | 2005-09-01 | To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia. |
| NCT00837252 ↗ | Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy | Completed | National Eye Institute (NEI) | Phase 1/Phase 2 | 2009-02-01 | Central serous chorioretinopathy (CSC) is a retinal disorder characterized by an accumulation of serous fluid under the retina. Although acute CSC tends to spontaneously resolve on its own with minimal sequelae, chronic CSC tends to persist and lead to irreversible visual loss. The pathogenesis of CSC is complex; however, systemic androgens have been implicated. Finasteride is an anti-androgen medication that is widely used in the treatment of various conditions. The objective of this study was to investigate the safety and potential efficacy of oral finasteride as a treatment for chronic CSC. Five participants with chronic CSC were enrolled into this uncontrolled, unmasked, Phase I/II study. An oral dose of finasteride, 5 mg daily, was administered to all participants for three months. Following this, finasteride was withheld and participants were observed for another three months. If a participant experienced a beneficial effect during the period in which he received finasteride and then experienced a relapse during the observation period, finasteride was re-instituted for the remaining period of the study. Relapse was defined as a return to the baseline maximum lesion height and/or return to baseline lesion volume. |
| NCT00842751 ↗ | Oral T7 Oral Testosterone in Man | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 | 2009-07-01 | The purpose of this study is to test how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future. |
| NCT00842751 ↗ | Oral T7 Oral Testosterone in Man | Completed | National Institutes of Health (NIH) | Phase 2 | 2009-07-01 | The purpose of this study is to test how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PROPECIA
Condition Name
Clinical Trial Locations for PROPECIA
Trials by Country
Clinical Trial Progress for PROPECIA
Clinical Trial Phase
Clinical Trial Sponsors for PROPECIA
Sponsor Name
| Sponsor Name for PROPECIA | |
| Sponsor | Trials |
| Dr. Reddy's Laboratories Limited | 2 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| National Institutes of Health (NIH) | 1 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
